Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C

Gastroenterology

Volumn 140, Issue 1, 2011, Pages 144-152.e2

  Rao, Gowtham A ^a,b   Pandya, Prashant K ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hepatitis C; Insulin; Metformin; Statins; Veterans

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMVASTATIN; SULFONYLUREA;

ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HEPATITIS C; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VETERAN; VIRUS LOAD;

EID: 78650457786     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.08.055     Document Type: Article

References (48)

1. S.H. Mehta, F.L. Brancati, and M.S. Sulkowski Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States Ann Intern Med 133 2000 592 599
2. H.B. El-Serag, H. Hampel, and C. Yeh Extrahepatic manifestations of hepatitis C among United States male veterans Hepatology 36 2002 1439 1445
3. S.J. Hadziyannis The spectrum of extrahepatic manifestations in hepatitis C virus infection J Viral Hepat 4 1997 9 28
4. S. Grimbert, P. Valensi, and C. Levy-Marchal High prevalence of diabetes mellitus in patients with chronic hepatitis C A case-control study Gastroenterol Clin Biol 20 1996 544 548
5. M.E. Allison, T. Wreghitt, and C.R. Palmer Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population J Hepatol 21 1994 1135 1139
6. M. Romero-Gmez, M. Del Mar Viloria, and R. Andrade Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
7. A. Monto, J. Alonzo, and J. Watson Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 36 2002 729 736
8. P. Marcellin, T. Asselah, and N. Boyer Fibrosis and disease progression in hepatitis C Hepatology 36 2002 S47 S56
9. B.J. Veldt, W. Chen, and E.J. Heathcote Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus Hepatology 47 2008 1856 1862
10. S.A. Harrison Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment Clin Gastroenterol Hepatol 6 2008 864 876
11. F. Negro, and M. Alaei Hepatitis C virus and type 2 diabetes World J Gastroenterol 15 2009 1537 1547
12. I. Konishi, N. Horiike, and Y. Hiasa Diabetes mellitus reduces the therapeutic effectiveness of interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C Hepatol Res 37 2007 331 336
13. H. Elgouhari, C. Zein, and I. Hanouneh Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection Dig Dis Sci 54 2009 2699 2705
14. J. McHutchison, E. Lawitz, and M. Shiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580
15. J.A. Dominitz, E.J. Boyko, and T.D. Koepsell Elevated prevalence of hepatitis C infection in users of United States veterans medical centers Hepatology 41 2005 88 96
16. L.I. Backus, D.B. Boothroyd, and B.R. Phillips Predictors of response of US veterans to treatment for the hepatitis C virus Hepatology 46 2007 37 47
17. C. Mallette, M. Flynn, and K. Promrat Outcome of screening for hepatitis C virus infection based on risk factors Am J Gastroenterol 103 2008 131 137
18. VA Information Resource Center VIReC research user guide: VHA decision support system clinical national data extracts 2nd ed. September 1, 2009 US Department of Veterans Affairs, Health Services Research and Development Service, VA Information Resource Center Hines, IL http://www.virec.research.va. gov/References/RUG/RUG-DSS-2nd-Ed-er.pdf Accessed 1 December 2010
19. US Department of Veterans Affairs, VA Information Resource Center (VIReC) VIReC research user guide: VHA pharmacy prescription data 2nd ed. September 2008 VIReC Hines, IL http://www.virec.research.va.gov/References/RUG/RUG.htm Accessed 1 December 2010
20. US Department of Veterans Affairs, VA Information Resource Center VIReC research user guide: VHA Medical SAS® outpatient datasets FY 2006 Edward J. Hines, Jr, VA Hospital September 2007 VIReC Hines, IL http://www.virec.research. va.gov/DataSourcesName/Medical-SAS-Datasets/SASdocumentation.htm Accessed 1 December 2010
21. K.A. McGinnis, M. Skanderson, and F.L. Levin Comparison of two VA laboratory data repositories indicates that missing data vary despite originating from the same source Medical Care 47 2009 121 124
22. T.L. Wright, and H.S. Yee VA Treatment recommendations for patients with chronic hepatitis C Fed Pract 20 1 2003 33
23. S. Zeuzem, E. Heathcote, and M. Shiffman Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C J Hepatol 39 2003 106 111
24. J.R. Kramer, T.P. Giordano, and J. Souchek Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era J Hepatol 42 2005 309 314
25. A.B. Adeel, L.F. Shawn, and C.K. Kwoh Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection Hepatology 40 2004 115 119
26. M.-W. Sohn, H. Zhang, and N. Arnold Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs Popul Health Metrics 4 2006 7
27. S.M. Grundy, J.I. Cleeman, and C.N. Bairey Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines J Am Coll Cardiol 44 2004 720 732
28. P. Kwo, E. Lawitz, and J. McCone HCV SPRINT-1: boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients Hepatology 48 2008 A1027
29. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
30. M. Manns, J. McHutchison, and S. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
31. P. Marotta, D. Hueppe, and E. Zehnter Efficacy of chronic hepatitis C therapy in community-based trials Clin Gastroenterol Hepatol 7 2009 1028 1036
32. J. Nachnani, S. Mathur, and R. Taylor T1004 metabolic syndrome, not adipocytokines, predicts clinically significant NAFLD in nongenotype 3 chronic hepatitis C (CHC) Gastroenterology 134 Suppl 1 2008 A-812 A-813
33. M.J. Walsh, J.R. Jonsson, M.M. Richardson, G.M. Lipka, D.M. Purdie, A.D. Clouston, and E.E. Powell Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 Gut 55 2006 529 535
34. M. Romero-Gomez, M. Diago, and R.J. Andrade Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin Hepatology 50 2009 1702 1708
35. K. Overbeck, D. Genne, and A. Golay Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin J Hepatol 49 2008 295 298
36. M. Khattab, M. Emad, and A. Abdelaleem Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance Liver Int 20 2009 447 454
37. D. Moradpour, F. Penin, and C. Rice Replication of hepatitis C virus Nat Rev Microbiol 5 2007 453 463
38. M. Monazahian, I. Bhme, and S. Bonk Low-density lipoprotein receptor as a candidate receptor for hepatitis C virus J Med Virol 57 1999 223 229
39. K. Gopal, T. Johnson, and S. Gopal Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment Hepatology 44 2006 335 340
40. D.M. Torres, and S.A. Harrison HCV replication and statin pleotropism: an adjuvant treatment panacea (quest) Am J Gastroenterol 103 2008 1390 1392
41. J. Ye, C. Wang, and R. Sumpter Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci U S A 100 2003 15865
42. S. Kapadia, and F. Chisari Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids Proc Natl Acad Sci U S A 102 2005 2561
43. T. Bader, J. Fazili, and M. Madhoun Fluvastatin inhibits hepatitis C replication in humans Am J Gastroenterol 103 2008 1383 1389
44. H. Sezaki, F. Suzuki, and N. Akuta An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads Intervirology 52 2009 43 48
45. M. Ikeda, K. Abe, and M. Yamada Different anti-HCV profiles of statins and their potential for combination therapy with interferon Hepatology 44 2006 117 125
46. L. Delang, J. Paeshuyse, and I. Vliegen Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development Hepatology 50 2009 6 16
47. C.K. Argo, P. Loria, and S.H. Caldwell Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48 2008 662 669
48. A. Lonardo, P. Loria, and M. Bertolotti Statins and HCV: a complex issue Hepatology 45 2007 257